• Donate
  • Contact
Canadian Association of Pompe
  • Home
  • About Us
    • Personal Stories
    • Our Partners
    • Newsletter
  • About Pompe
  • Blog
  • Links
  • Connections
Select Page
Genzyme Study of Myozyme® for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints

Genzyme Study of Myozyme® for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints

by CAP | Dec 13, 2007 | Press Releases

Recent Posts

  • Amicus Therapeutics Provides Updates for AT-GAA for Pompe Disease
  • IPA Update – Q4 2019
  • Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics
  • Audentes Therapeutics Update on Pompe and Other Programs
  • 2019 CAP Annual General Meeting
  • Terms
  • Privacy

Copyright © 2006 - 2020 Canadian Association of Pompe | Developed by PacificByte

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok